Revolution Medicines Starts Phase 3 Trial of RASONQUE Combo in First-Line Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $45.605.
Summary
Revolution Medicines has begun dosing patients in RASolute 309, a global Phase 3 trial testing RASONQUE (daraxonrasib) plus zoldonrasib as first-line treatment for metastatic RAS G12D pancreatic cancer. This is the first Phase 3 study of a RAS(ON) inhibitor doublet, targeting the most common RAS mutation in pancreatic cancer. The trial compares the combination against standard-of-care gemcitabine/nab-paclitaxel, with dual primary endpoints of progression-free survival and overall survival. This follows the August FDA approval of RASONQUE for previously treated metastatic pancreatic cancer and the September breakthrough therapy designation for the combination. The move expands the company's commercial opportunity into the first-line setting, where the patient population is larger and treatment options remain limited. No data readout timeline was provided, but the trial's initiation marks a key step in the company's registrational strategy.
At the time of this announcement, RVMD was trading at $207.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.3B. The 52-week trading range was $45.61 to $224.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.